The complement system and autoimmune diseases

被引：3

作者：

Jia Changhao ^{[1
,2
]}

Tan Ying ^{[1
]}

Zhao Minghui ^{[1
,2
,3
]}

机构：

[1] Laboratory of Renal Disease, Department of Medicine, Renal Division, Ministry of Health of China, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China

[2] Peking-Tsinghua Center for Life Sciences, Beijing, China

[3] Center for Interdisciplinary Research in Biomedicine, Peking University, Beijing, China

来源：

慢性疾病与转化医学（英文） | 2022年 / 08卷 / 03期

关键词：

ANCA-associated vasculitides; antiphospholipid syndrome; autoimmune disease; complement; systemic lupus erythematosus;

D O I：

暂无

中图分类号：

R593.2 [自身免疫性疾病、结缔组织疾病];

学科分类号：

1002 ; 100201 ;

摘要：

The complement system plays a key role in the pathogenesis of autoimmune diseases, which usually injures the kidney. More and more studies have shown the pathogenic role and indicated that abnormal activation of the complement system was highly involved in the outbreak of autoimmune diseases. This review mainly introduced recent studies of complement system activation contributing to the pathogenesis of autoimmune diseases, including systemic lupus erythematosus, antiphospholipid syndrome, antineutrophil cytoplasmic antibody-associated vasculitides, and so on. Understanding the pathogenic roles of complement activation in various autoimmune diseases will identify potential novel therapeutic targets on complement systems.

引用

页码：184 / 190

页数：7

共 39 条

[1]

Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity[J] . Mannes Marco,Dopler Arthur,Zolk Oliver,Lang Sophia J.,Halbgebauer Rebecca,H?chsmann Britta,Skerra Arne,Braun Christian K.,Huber-Lang Markus,Schrezenmeier Hubert,Schmidt Christoph Q..Blood . 2021 (4)

[2]

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria[J] . Prajakta Badri,Xuemin Jiang,Anna Borodovsky,Nader Najafian,Jae Kim,Valerie A. Clausen,Varun Goel,Bahru Habtemariam,Gabriel J. Robbie.Clinical pharmacokinetics . 2020 (prep)

[3]

Anti-complement factor H autoantibodies may be protective in lupus nephritis[J] . Lin-Lin Li,Ying Tan,Di Song,Yong-Zhe Li,Feng Yu,Min Chen,Ming-Hui Zhao.Clinica Chimica Acta . 2020 (prep)

[4] C1q A08 Is a Half-Cryptic Epitope of Anti-C1q A08 Antibodies in Lupus Nephritis and Important for the Activation of Complement Classical Pathway [J].

Wu, Wen-Jun ;

Tan, Ying ;

Liu, Xiao-Ling ;

Yu, Feng ;

Zhao, Ming-Hui .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[5] The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria [J].

Roeth, Alexander ;

Nishimura, Jun-ichi ;

Nagy, Zsolt ;

Gaal-Weisinger, Julia ;

Panse, Jens ;

Yoon, Sung-Soo ;

Egyed, Miklos ;

Ichikawa, Satoshi ;

Ito, Yoshikazu ;

Kim, Jin Seok ;

Ninomiya, Haruhiko ;

Schrezenmeier, Hubert ;

Sica, Simona ;

Usuki, Kensuke ;

de Fontbrune, Flore Sicre ;

Soret, Juliette ;

Sostelly, Alexandre ;

Higginson, James ;

Dieckmann, Andreas ;

Gentile, Brittany ;

Anzures-Cabrera, Judith ;

Shinomiya, Kenji ;

Jordan, Gregor ;

Biedzka-Sarek, Marta ;

Klughammer, Barbara ;

Jahreis, Angelika ;

Bucher, Christoph ;

de Latour, Regis Peffault .

BLOOD, 2020, 135 (12) :912-920

[6]

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial[J] . James F. Howard,Richard J. Nowak,Gil I. Wolfe,Miriam L. Freimer,Tuan H. Vu,John L. Hinton,Michael Benatar,Petra W. Duda,James E. MacDougall,Ramin Farzaneh-Far,Henry J. Kaminski,Richard Barohn,Mazen Dimachkie,Mamatha Pasnoor,Constantine Farmakidis,

[7] Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS [J].

Chaturvedi, Shruti ;

Braunstein, Evan M. ;

Yuan, Xuan ;

Yu, Jia ;

Alexander, Alice ;

Chen, Hang ;

Gavriilaki, Eleni ;

Alluri, Ravi ;

Streiff, Michael B. ;

Petri, Michelle ;

Crowther, Mark A. ;

McCrae, Keith R. ;

Brodsky, Robert A. .

BLOOD, 2020, 135 (04) :239-251

[8]

Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy[J] . Richard Lafayette,Brad H. Rovin,Heather N. Reich,James A. Tumlin,Jürgen Floege,Jonathan Barratt.Kidney International Reports . 2020 (prep)

[9] Association of MBL-2 gene polymorphisms with systemic lupus erythematosus: an updated meta-analysis and trial sequential analysis [J].

Mahto, Harishankar ;

Pati, Abhijit ;

Sahu, Sushil K. ;

Sharma, Hanuman Prasad ;

Padhi, Archana ;

Panda, Aditya K. .

LUPUS, 2020, 29 (10) :1227-1237

[10] Complement in the Pathophysiology of the Antiphospholipid Syndrome [J].

Chaturvedi, Shruti ;

Brodsky, Robert A. ;

McCrae, Keith R. .

FRONTIERS IN IMMUNOLOGY, 2019, 10

← 1 2 3 4 →